ACE2/Angiotensin-(1-7)/Mas axis and cardiovascular regeneration

Yagna P R Jarajapu, Maria B. Grant, Mohan K. Raizada

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Discovery of angiotensin converting enzyme (ACE)-2 provided a strong impetus for the development of novel therapeutic tools for the treatment of cardiovascular diseases (CVDs). Angiotensin (Ang)-(1-7), the product of ACE2, via activation of Mas receptor elicits cardiovascular protective effects to a large extent by counter-regulating ACE/Ang-II/AT1-receptor axis of renin angiotensin system (RAS). Bone marrow (BM)-derived progenitor cells play an important role in cardiovascular homeostasis. Angiogenic precursor cells (APCs) have received tremendous attention in the recent years for their therapeutic application for treatment of CVDs, where cardiovascular tissue regeneration is the desired outcome. Autologous cell therapy is a better treatment option for patients with cardiovascular complications. However, circulating APCs from these patients are dysfunctional limiting their therapeutic utility. Thus ex vivo modification to restore their regenerative potential is essential to improve outcomes of autologous cell therapies in CVD. Members of both pathological and protective axes of RAS have been identified in one or more types of BM-derived cells. Modulation of the function of APCs by Ang-II or Ang-(1-7) has now been implicated in the pathology and protection of cardiovascular systems, respectively. Thus, novel functions of RAS in the cardiovascular regenerative physiology and pharmacology are being unraveled. Accumulating evidence points to the ACE2/Ang-(1-7)/Mas axis as a promising target for the treatment of CVDs. The major focus of this review is to highlight the protective role of ACE2/Ang-(1-7)/Mas pathway in the reparative function of BM-derived cells for cardiovascular repair and regeneration.

Original languageEnglish (US)
Pages (from-to)35-46
Number of pages12
JournalCurrent Hypertension Reviews
Volume8
Issue number1
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Regeneration
Cardiovascular Diseases
Renin-Angiotensin System
Cell- and Tissue-Based Therapy
Bone Marrow Cells
Therapeutics
Cardiovascular Physiological Phenomena
Angiotensin Type 1 Receptor
Angiotensin Receptors
Peptidyl-Dipeptidase A
Cardiovascular System
angiotensin I (1-7)
Angiotensin II
Homeostasis
Stem Cells
Bone Marrow
Pharmacology
Pathology

Keywords

  • ACE2
  • Angiogenic precursor cells
  • Angiotensin-(1-7)
  • Cardiovascular regeneration
  • Mas receptor

ASJC Scopus subject areas

  • Internal Medicine

Cite this

ACE2/Angiotensin-(1-7)/Mas axis and cardiovascular regeneration. / Jarajapu, Yagna P R; Grant, Maria B.; Raizada, Mohan K.

In: Current Hypertension Reviews, Vol. 8, No. 1, 2012, p. 35-46.

Research output: Contribution to journalArticle

Jarajapu, Yagna P R ; Grant, Maria B. ; Raizada, Mohan K. / ACE2/Angiotensin-(1-7)/Mas axis and cardiovascular regeneration. In: Current Hypertension Reviews. 2012 ; Vol. 8, No. 1. pp. 35-46.
@article{01d703457b16486c83f8a74464b5445e,
title = "ACE2/Angiotensin-(1-7)/Mas axis and cardiovascular regeneration",
abstract = "Discovery of angiotensin converting enzyme (ACE)-2 provided a strong impetus for the development of novel therapeutic tools for the treatment of cardiovascular diseases (CVDs). Angiotensin (Ang)-(1-7), the product of ACE2, via activation of Mas receptor elicits cardiovascular protective effects to a large extent by counter-regulating ACE/Ang-II/AT1-receptor axis of renin angiotensin system (RAS). Bone marrow (BM)-derived progenitor cells play an important role in cardiovascular homeostasis. Angiogenic precursor cells (APCs) have received tremendous attention in the recent years for their therapeutic application for treatment of CVDs, where cardiovascular tissue regeneration is the desired outcome. Autologous cell therapy is a better treatment option for patients with cardiovascular complications. However, circulating APCs from these patients are dysfunctional limiting their therapeutic utility. Thus ex vivo modification to restore their regenerative potential is essential to improve outcomes of autologous cell therapies in CVD. Members of both pathological and protective axes of RAS have been identified in one or more types of BM-derived cells. Modulation of the function of APCs by Ang-II or Ang-(1-7) has now been implicated in the pathology and protection of cardiovascular systems, respectively. Thus, novel functions of RAS in the cardiovascular regenerative physiology and pharmacology are being unraveled. Accumulating evidence points to the ACE2/Ang-(1-7)/Mas axis as a promising target for the treatment of CVDs. The major focus of this review is to highlight the protective role of ACE2/Ang-(1-7)/Mas pathway in the reparative function of BM-derived cells for cardiovascular repair and regeneration.",
keywords = "ACE2, Angiogenic precursor cells, Angiotensin-(1-7), Cardiovascular regeneration, Mas receptor",
author = "Jarajapu, {Yagna P R} and Grant, {Maria B.} and Raizada, {Mohan K.}",
year = "2012",
doi = "10.2174/157340212800505025",
language = "English (US)",
volume = "8",
pages = "35--46",
journal = "Current Hypertension Reviews",
issn = "1573-4021",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - ACE2/Angiotensin-(1-7)/Mas axis and cardiovascular regeneration

AU - Jarajapu, Yagna P R

AU - Grant, Maria B.

AU - Raizada, Mohan K.

PY - 2012

Y1 - 2012

N2 - Discovery of angiotensin converting enzyme (ACE)-2 provided a strong impetus for the development of novel therapeutic tools for the treatment of cardiovascular diseases (CVDs). Angiotensin (Ang)-(1-7), the product of ACE2, via activation of Mas receptor elicits cardiovascular protective effects to a large extent by counter-regulating ACE/Ang-II/AT1-receptor axis of renin angiotensin system (RAS). Bone marrow (BM)-derived progenitor cells play an important role in cardiovascular homeostasis. Angiogenic precursor cells (APCs) have received tremendous attention in the recent years for their therapeutic application for treatment of CVDs, where cardiovascular tissue regeneration is the desired outcome. Autologous cell therapy is a better treatment option for patients with cardiovascular complications. However, circulating APCs from these patients are dysfunctional limiting their therapeutic utility. Thus ex vivo modification to restore their regenerative potential is essential to improve outcomes of autologous cell therapies in CVD. Members of both pathological and protective axes of RAS have been identified in one or more types of BM-derived cells. Modulation of the function of APCs by Ang-II or Ang-(1-7) has now been implicated in the pathology and protection of cardiovascular systems, respectively. Thus, novel functions of RAS in the cardiovascular regenerative physiology and pharmacology are being unraveled. Accumulating evidence points to the ACE2/Ang-(1-7)/Mas axis as a promising target for the treatment of CVDs. The major focus of this review is to highlight the protective role of ACE2/Ang-(1-7)/Mas pathway in the reparative function of BM-derived cells for cardiovascular repair and regeneration.

AB - Discovery of angiotensin converting enzyme (ACE)-2 provided a strong impetus for the development of novel therapeutic tools for the treatment of cardiovascular diseases (CVDs). Angiotensin (Ang)-(1-7), the product of ACE2, via activation of Mas receptor elicits cardiovascular protective effects to a large extent by counter-regulating ACE/Ang-II/AT1-receptor axis of renin angiotensin system (RAS). Bone marrow (BM)-derived progenitor cells play an important role in cardiovascular homeostasis. Angiogenic precursor cells (APCs) have received tremendous attention in the recent years for their therapeutic application for treatment of CVDs, where cardiovascular tissue regeneration is the desired outcome. Autologous cell therapy is a better treatment option for patients with cardiovascular complications. However, circulating APCs from these patients are dysfunctional limiting their therapeutic utility. Thus ex vivo modification to restore their regenerative potential is essential to improve outcomes of autologous cell therapies in CVD. Members of both pathological and protective axes of RAS have been identified in one or more types of BM-derived cells. Modulation of the function of APCs by Ang-II or Ang-(1-7) has now been implicated in the pathology and protection of cardiovascular systems, respectively. Thus, novel functions of RAS in the cardiovascular regenerative physiology and pharmacology are being unraveled. Accumulating evidence points to the ACE2/Ang-(1-7)/Mas axis as a promising target for the treatment of CVDs. The major focus of this review is to highlight the protective role of ACE2/Ang-(1-7)/Mas pathway in the reparative function of BM-derived cells for cardiovascular repair and regeneration.

KW - ACE2

KW - Angiogenic precursor cells

KW - Angiotensin-(1-7)

KW - Cardiovascular regeneration

KW - Mas receptor

UR - http://www.scopus.com/inward/record.url?scp=84870211522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870211522&partnerID=8YFLogxK

U2 - 10.2174/157340212800505025

DO - 10.2174/157340212800505025

M3 - Article

VL - 8

SP - 35

EP - 46

JO - Current Hypertension Reviews

JF - Current Hypertension Reviews

SN - 1573-4021

IS - 1

ER -